Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 3/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | ANPEP | P15144 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31080852 | 1.00 | PTPN1 (0.43) | PTPN1MMP2ANPEPMAPK1HSD17B10 | |
| SCHEMBL877760 | 1.00 | PTPN1 (0.43) | PTPN1MMP2ANPEPMAPK1HSD17B10 | |
| SCHEMBL85062 | 0.90 | PTPN1 (0.52) | PTPN1MMP2ANPEPHSD17B10NPC1 | |
| SCHEMBL719488 | 0.90 | PTPN1 (0.52) | PTPN1MMP2ANPEPHSD17B10NPC1 | |
| SCHEMBL719489 | 0.90 | PTPN1 (0.52) | PTPN1MMP2ANPEPHSD17B10NPC1 | |
| SCHEMBL12349532 | 0.89 | PTPN1 (0.40) | PTPN1MMP2ANPEPMAPK1HSD17B10 | |
| SCHEMBL8274213 | 0.88 | PTPN1 (0.40) | PTPN1MMP2ANPEPMAPK1HSD17B10 | |
| SCHEMBL85511 | 0.87 | HSD17B10 (0.43) | PTPN1MMP2ANPEPHSD17B10CHRM2 | |
| SCHEMBL13059380 | 0.87 | CHRM2 (0.39) | PTPN1MMP2ANPEPHSD17B10CHRM2 | |
| SCHEMBL204966 | 0.87 | HSD17B10 (0.43) | PTPN1MMP2ANPEPHSD17B10CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4107166-B1 | HETEROARYL COMPOUNDS FOR TREATMENT OF COMPLEMENT FACTOR D MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS INC (US) | 2026-05-27 | — | — | EP | disclosed |
| CN-121202748-A | Preparation method of N-BOC-4-oxo-proline tert-butyl ester | 南京红杉生物科技有限公司 | 2025-12-26 | — | — | CN | disclosed |
| CN-121202748-A | Preparation method of N-BOC-4-oxo-proline tert-butyl ester | 南京红杉生物科技有限公司 | 2025-12-26 | — | — | CN | disclosed |
| US-20250197403-A1 | HETEROARYL COMPOUNDS FOR TREATMENT OF COMPLEMENT FACTOR D MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2025-06-19 | — | — | US | disclosed |
| US-20240317748-A1 | CARBONYL SUBSTITUTED DIAZASPIRO COMPOUNDS AND ITS USE | BIONOVA PHARMACEUTICALS LTD. (KY) | 2024-09-26 | — | — | US | disclosed |
| CN-118256591-A | Cyclic peptide compound having high membrane permeability and library comprising same | 中外制药株式会社 | 2024-06-28 | — | — | CN | disclosed |
| CN-110869544-B | Cyclic peptide compound having high membrane permeability and library comprising same | 中外制药株式会社 | 2024-03-08 | — | — | CN | disclosed |
| US-20230357199-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2023-11-09 | — | — | US | disclosed |
| EP-4271676-A1 | CARBONYL SUBSTITUTED DIAZASPIRO COMPOUNDS AND ITS USE | Bionova Pharmaceuticals (Shanghai) Limited (CN) | 2023-11-08 | — | — | EP | disclosed |
| WO-2023180189-A1 | MPRO TARGETING ANTIVIRAL COMPOUNDS | EXSCIENTIA AI LIMITED (GB) | 2023-09-28 | — | — | WO | disclosed |
| US-20100272681-A1 | Inhibitors of Serine Proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-10-28 | — | — | US | disclosed |
| US-20100272681-A1 | Inhibitors of Serine Proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-10-28 | — | — | US | disclosed |
| US-20100272681-A1 | Inhibitors of Serine Proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-10-28 | — | — | US | disclosed |
| US-20100029611-A1 | S1P1 receptor agonists and use thereof | AMGEN INC. (US) | 2010-02-04 | — | — | US | disclosed |
| WO-2009154775-A1 | S1P1 RECEPTOR AGONISTS AND USE THEREOF | AMGEN INC. (US) | 2009-12-23 | — | — | WO | disclosed |
| EP-2134717-A2 | INHIBITORS OF SERINE PROTEASES | Vertex Pharmceuticals Incorporated (US) | 2009-12-23 | — | — | EP | disclosed |
| WO-2009152824-A1 | HETEROCYCLIC DERIVATIVES AS IAP BINDING COMPOUNDS | NUEVOLUTION A/S (DK) | 2009-12-23 | — | — | WO | disclosed |
| WO-2008106058-A2 | INHIBITORS OF SERINE PROTEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-09-04 | — | — | WO | disclosed |
| WO-2008106058-A2 | INHIBITORS OF SERINE PROTEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-09-04 | — | — | WO | disclosed |
| US-5821261-A | ADMINISTERING IN THE TREATMENT OF NEURODEGENERATIVE DISORDERS, DISORDERS OF GASTROINTESTINAL MOTILITY AND INFLAMMATION | MERCK & CO., INC. (US) | 1998-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240317748-A1 | CARBONYL SUBSTITUTED DIAZASPIRO COMPOUNDS AND ITS USE | SDHA, PDHA1, GLS | PTPN1 4092/4885MMP2 3660/4885ANPEP 1608/4885 |
| US-20100029611-A1 | S1P1 receptor agonists and use thereof | S1PR1, S1PR5, S1PR2 | PTPN1 1228/4885MMP2 4438/4885ANPEP 3070/4885 |
| US-20230357199-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | CFD, TFPI, CFH | PTPN1 1842/4885MMP2 927/4885ANPEP 343/4885 |
| US-20250197403-A1 | HETEROARYL COMPOUNDS FOR TREATMENT OF COMPLEMENT FACTOR D MEDIATED DISORDERS | CFD, CFH, TFPI | PTPN1 2797/4885MMP2 2910/4885ANPEP 1278/4885 |
| US-20100272681-A1 | Inhibitors of Serine Proteases | SERPINB1, PRSS1, SPINT2 | PTPN1 1064/4885MMP2 319/4885ANPEP 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.